Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

Neeraj Agarwal, MD
Published: Wednesday, Dec 27, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Several AR inhibitors are being tested in the first-line setting, such as apalutamide, explains Agarwal. In the next 2 or 3 years, there will be multiple new AR inhibitors with their own benefits and adverse events.

According to Agarwal, it will be challenging for community oncologists to determine the ideal choice for patients with prostate cancer.
 


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Several AR inhibitors are being tested in the first-line setting, such as apalutamide, explains Agarwal. In the next 2 or 3 years, there will be multiple new AR inhibitors with their own benefits and adverse events.

According to Agarwal, it will be challenging for community oncologists to determine the ideal choice for patients with prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x